Importance of specialized centers in diagnosis and treatment of extremitiy-soft tissue sarcomas: Review of 603 cases;Die Bedeutung von Referenzzentren in Diagnose und Therapie von Weichgewebssarkomen der Ëxtremitaten: Auswërtung von 603 Fallen

Chirurg

Volumn 80, Issue 4, 2009, Pages 341-347

  Lehnhardt, M ^a   Daigeler, A ^a   Homann, H H ^a   Hauser, J ^a   Langer, S ^a   Steinstraßer L ^a   Soimaru, C ^a   Puls, A ^a   Steinau, H U ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

Chemotherapy; Expert second opinion; Grading; Radiation; Soft tissue sarcoma

Indexed keywords

EID: 67349126543     PISSN: 00094722     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00104-008-1562-2     Document Type: Article

References (44)

1. Abt AB, Abt LG, Olt GJ (1995) The effect of interinstitution anatomic pathology consultation on patient care. Arch Pathol Lab Med 119:514-517
2. Arbiser ZK, Folpe AL, Weiss SW (2001) Consultative (expert) second opinions in soft tissue pathology. Analysis of problem-prone diagnostic situations. Am J Clin Pathol 116:473-476
3. Arbogast S, Baretton G, Hillemanns M, Meister P (1999) Mikroskopische Befundung von Weichgewebstumoren. In: Issels R (Hrsg) Knochentumoren Weichteilsarkome. 3. Aufl. Schriftenreihe des Tumorzentrums München mit Empfehlungen zur Diagnostik, Therapie und Nachsorge.Tumorzentrum München, S 22-36
4. Bickels J, Jelinek JS, Shmookler BM et al. (1999) Biopsy of musculoskeletal tumors. Current concepts. Clin Orthop 368:212-219
5. Campanacci M (1999) Aggressive fibromatosis. In: Campanacci M (ed) Bone and soft tissue tumors. 2nd edn. Springer, Berlin Heidelberg New York, pp925-936
6. Campanacci M (1999) Leiomyosarcoma. In: Campanacci M (ed) Bone and soft tissue tumors 2nd edn. Springer, Berlin Heidelberg New York, pp1025-1031
7. Clarkson P, Ferguson PC (2004) Management of soft tissue sarcomas of the extremities. Expert Rev Anticancer Ther 4:237-246
8. Clarkson P, Ferguson PC (2004) Primary multi-disciplinary management of extremity soft tissue sarcomas. Curr Treat Options Oncol 5:451-462
9. Coindre JM (1993) Pathology and grading of soft tissue sarcomas. Cancer Treat Res 67:1-22
10. Coindre JM, Blanc-Vincent MP, Collin F et al. (2001) Standards, options and recommendations: practice guidelines for difficult diagnosis in surgical pathology or cytopathology in cancer patients. Bull Cancer 88:765-773
11. Coindre JM, Trojani M, Contesso G et al. (1986) Reproducibility of a histopathologic grading system for adult soft tissue sarcoma. Cancer 58:306-309
12. Cormier JN, Langstein HN, Pisters PW (2004) Preoperative therapy for soft tissue sarcoma. Cancer Treat Res 120:43-63
13. Fernberg JO, Hall KS (2004) Chemotherapy in soft tissue sarcoma.The Scandinavian Sarcoma Group experience. Acta Orthop Scand Suppl 75:77-86
14. Fletcher CD (1992) Pleomorphic malignant fibrous histiocytoma: fact or fiction? A critical reappraisal based on 159 tumors diagnosed as pleomorphic sarcoma. Am J Surg Pathol 16:213-228
15. Fletcher CD (2006) The evolving classification of soft tissue tumours: an update based on the new WHO classification. Histopathology48:3-12
16. Harris M, Hartley AL, Blair V et al. (1991) Sarcomas in north west England: I. Histopathological peer review. Br J Cancer 64:315-320
17. Hartmann JT, Oechsle K, Huober J et al. (2006) An open label, non-comparative phase Il study of gemcitabine as salvage treatment for patients with pretreated adult type soft tissue sarcoma. Invest New Drugs 24:249-253
18. Hartmann JT, Patel S (2005) New drug developments for patients with metastatic soft tissue sarcoma. Curr Oncol Rep 7:300-306
19. Hasegawa T, Yamamoto S, Nojima T et al. (2002) Validity and reproducibility of histologic diagnosis and grading for adult soft-tissue sarcomas. Hum Pathol 33:111-115
20. Hashimoto H (1995) Incidence of soft tissue sarcomas in adults. In: Harms D, Schmidt D (eds) Current topics in pathology. Springer, Berlin Heidelberg New York, pp 1-16
21. Hauser J, Drucke D, Lehnhardt M et al. (2007) Unclear soft-tissue tumor. Chirurg 78:62-64
22. Hillemanns M (1999) Experimentelle Methoden. I. Zytogenetische Untersuchungen an Knochenund Weichteiltumoren. In: lssels R (Hrsg) Knochentumoren Weichteilsarkome 3. Aufl. Schriftenreihe des Tumorzentrums München mit Empfehlungen zur Diagnostik, Therapie und Nachsorge. Tumorzentrum München, S 37-41
23. Issels R, Sauer H (1999) Weichteilsarkome Allgemeine Informationen. In: Issels R (Hrsg) Knochentumoren Weichteilsarkome Schriftenreihe des Tumorzentrums München mit Empfehlungen zur Diagnostik, Therapie und Nachsorge. Tumorzentrum München, S 115-136
24. Issels RD (2006) High-risk soft tissue sarcoma: clinical trial and hyperthermia combined chemotherapy. Int J Hyperthermia 22:235-239
25. Issels RD, Schlemmer M, Lindner LH (2006) The role of hyperthermia In combined treatment In the management of soft tissue sarcoma. Curr Oncol Rep 8:305-309
26. Katenkamp D (1988) Cellular heterogeneity. Explanation for changing of tumor phenotype and biologic behavior in soft tissue sarcomas. Pathol Res Pract 183:698-705
27. Katenkamp D (1997) Morphologie und Molekularbiologie maligner Weichgewebstu moren. In: Roth SL (Hrsg) Klinische Onkologie. Hans-Huber, Bern Göttingen S 295-300
28. Katenkamp D, Kosmehl H (1995) Heterogeneity in malignant soft tissue tumors. Curr Top Pathol 89: 123-151
29. Kilpatrick SE (1999) Histologic prognostication in soft tissue sarcomas: grading versus subtyping or both? A comprehensive review of the literature with proposed practical guidelines. Ann Diagn Pathol 3:48-61
30. Kronz JD, Westra WH, Epstein JI (1999) Mandatory second opinion surgical pathology at a large referral hospital. Cancer 86:2426-2435
31. Lehnhardt M, Daigeler A, Häuser Jetai. (2008) The value of expert second opinion in diagnosis of soft tissue sarcomas. J Surg Oncol 97:40-43
32. Lehnhardt M, Kuhnen C, Drucke D et al. (2004) Liposarcoma of the extremities: recent developments in surgical therapy-analysis of 167 patients. Chirurg 75:1182-1190
33. Mankin HJ, Mankin CJ, Simon MA (1996) The hazards of the biopsy, revisited. Members of the Musculoskeletal Tumor Society. J Bone Joint Surg Am 78:656-663
34. Nakayama R, Nemoto T, Takahashi H et al. (2007) Gene expression analysis of soft tissue sarcomas: characterization and reclassification of malignant fibrous histiocytoma. Mod Pathol 20:749-759
35. Poremba C (2006) Soft tissue sarcomas: the role of histology and molecular pathology for differential diagnosis. Verh Dtsch Ges Pathol 90:59-72
36. Puis A (2004) Die Berechtigung der Referenzpathologie zur Diagnostik maligner Weichgewebstumoren. Promotionsarbeit, Ruhr-Universität Bochum
37. Reichardt P (2002) High-dose chemotherapy in adult soft tissue sarcoma. Crit Rev Oncol Hematol 41:157-167
38. Reichardt P, Oechsle K, Pink D et al. (2003) An open label, non-comparative phase II study of topotecan as salvage treatment for patients with soft tissue sarcoma. Invest New Drugs 21:481-486
39. Singer S, Demetri GD, Baldini EH, Fletcher CD (2000) Management of soft-tissue sarcomas: an overview and update. Lancet Oncol 1:75-85
40. Steinau HU, Homann HH, Drucke D et al. (2001) Resection method and functional restoration in soft tissue sarcomas of the extremities. Chirurg 72: 501-513
41. Steinau HU, Soimaru C, Puis A et al. (2002) Chirurgische Onkologie der Weichgewebssarkome. Ist eine Referenzpathologie erforderlich? Deutsche Gesellschaft für Chirurgie, Kongressband: 463
42. Svancarova L, Blay JY, Judson IR et al. (2002) Gemcitabine in advanced adult soft-tissue sarcomas. A phase Il study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 38:556-559
43. Tomaszewski JE, Bear HD, Connally JA et al. (2000) Consensus conference on second opinions in diagnostic anatomic pathology. Who, What, and When. Am J Clin Pathol 114:329-335
44. Worth AJ (1988) Role of the pathologist in the management of soft-tissue sarcomas. Can J Surg 31:404-406